首页> 外文OA文献 >Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe
【2h】

Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe

机译:基因组测序能力,数据保留以及欧洲原始数据的个人访问

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Whole genome/exome sequencing (WGS/WES) has become widely adopted in research and, more recently, in clinical settings. Many hope that the information obtained from the interpretation of these data will have medical benefits for patients and—in some cases—also their biological relatives. Because of the manifold possibilities to reuse genomic data, enabling sequenced individuals to access their own raw (uninterpreted) genomic data is a highly debated issue. This paper reports some of the first empirical findings on personal genome access policies and practices. We interviewed 39 respondents, working at 33 institutions in 21 countries across Europe. These sequencing institutions generate massive amounts of WGS/WES data and represent varying organisational structures and operational models. Taken together, in total, these institutions have sequenced ∼317,259 genomes and exomes to date. Most of the sequencing institutions reported that they are able to store raw genomic data in compliance with various national regulations, although there was a lack of standardisation of storage formats. Interviewees from 12 of the 33 institutions included in our study reported that they had received requests for personal access to raw genomic data from sequenced individuals. In the absence of policies on how to process such requests, these were decided on an ad hoc basis; in the end, at least 28 requests were granted, while there were no reports of requests being rejected. Given the rights, interests, and liabilities at stake, it is essential that sequencing institutions adopt clear policies and processes for raw genomic data retention and personal access.
机译:全基因组/外壳测序(WGS / WES)已在研究中被广泛采用,最近在临床环境中得到广泛采用。许多人希望从解释这些数据中获得的信息将对患者的医疗益处和 - 在某些情况下 - 也是他们的生物亲属。由于歧管可能性来重用基因组数据,使能测序的个体可以访问自己的原始(未解释的)基因组数据是一个高度讨论的问题。本文报告了一些关于个人基因组访问政策和实践的实证调查结果。我们采访了39名受访者,在欧洲的21个国家的33个机构工作。这些测序机构产生大量的WG / WES数据,并表示不同的组织结构和操作模型。总共占据这些机构的迄今为止,这些机构对〜317,259个基因组和溢出进行了测序。大多数排序机构报告说,他们能够遵守各种国家法规的原始基因组数据,尽管缺乏储存格式标准化。我们研究中包含的33个机构中有12个的受访者报告说,他们已收到对来自测序的个体的个人获得对原因组数据的请求。在没有关于如何处理此类请求的政策的情况下,这些是根据特设的基础决定;最后,至少有28个请求,而没有被拒绝请求的报告。鉴于股权的权利,利益和负债,必须对原始基因组数据保留和个人访问的明确政策和流程采用明确的政策和流程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号